DGAP-Adhoc: Evotec SE to acquire Just Biotherapeutics, Inc.

2019. május 20., hétfő, 22:24





DGAP-Ad-hoc: Evotec SE / Key word(s): Takeover


Evotec SE to acquire Just Biotherapeutics, Inc.


20-May-2019 / 22:24 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash.



Just.Bio is a unique technology company that integrates highly synergistic scientific expertise and technologies for design, development, and manufacturing of biologics. The acquisition grows Evotec"s business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle, WA, USA.



The completion of the transaction is subject to customary closing conditions. The acquisition is expected to close in the second quarter of 2019.



- End of ad hoc notification -



Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)40560 81-242, werner.lanthaler@evotec.com











20-May-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de





























Language: English
Company: Evotec SE

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg

Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 813731





 
End of Announcement DGAP News Service




813731  20-May-2019 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=813731&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.